Evolution of Practical Recommendations for the Management of Diabetes in Patients with COVID-19: An Experimental Observational Study
DOI:
https://doi.org/10.61280/2qm2c852Keywords:
COVID-19, Diabetes Mellitus, Glycemic Control, Insulin Therapy, Knowledge Assessment, Experimental ManagementAbstract
Background: Diabetes mellitus emerged as one of the most significant comorbidities influencing the severity and outcomes of COVID-19. The dynamic nature of the pandemic necessitated continuous evolution of practical diabetes management strategies, especially in hospitalized and home-isolated patients.
Objectives: To evaluate the evolution and effectiveness of structured, practical diabetes management recommendations on glycemic control and COVID-19 outcomes among patients with Type 2 diabetes mellitus (T2DM).
Methods: This prospective observational study with an embedded experimental management approach was conducted over 18 months (January 2021–June 2022) at a tertiary-care teaching hospital. A total of 220 RT-PCR–confirmed COVID-19 patients with T2DM were enrolled. Baseline socio-demographic, clinical, biochemical, and knowledge assessments were performed, followed by standardized glycemic optimization, COVID-19-specific management, and reinforced education. Glycemic parameters, inflammatory markers, clinical severity, and recovery outcomes were compared pre- and post-management.
Results: Post-intervention analysis demonstrated significant improvement in fasting and post-prandial blood glucose levels, reduction in HbA1c, and better stabilization of inflammatory markers. Patients with improved glycemic control showed reduced oxygen requirement, shorter hospital stay, and faster symptom resolution. Knowledge scores improved significantly following structured counselling.
Conclusion: Practical, adaptable diabetes management strategies significantly improve glycemic stability and COVID-19 outcomes. Continuous reinforcement of patient education and protocol-driven glucose monitoring plays a pivotal role during pandemic-related healthcare disruptions.
Downloads
References
1. Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-1077.e3. doi:10.1016/j.cmet.2020.04.021
2. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550. doi:10.1016/S2213-8587(20)30152-2
3. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782-792. doi:10.1016/S2213-8587(20)30238-2
4. Ceriello A, Standl E, Catrinoiu D, et al. Issues of diabetes management in people with diabetes and COVID-19 in ICU settings. Diabetes Care. 2020;43(7):1529-1534. doi:10.2337/dc20-1247
5. Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by COVID-19. Diabetes Care. 2020;43(7):e77-e78. doi:10.2337/dc20-0723
6. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):e3319. doi:10.1002/dmrr.3319
7. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11-30. doi:10.1038/s41574-020-00435-4
8. Drucker DJ. Coronavirus infections and type 2 diabetes—shared pathways with therapeutic implications. Endocr Rev. 2020;41(3):bnaa011. doi:10.1210/endrev/bnaa011
9. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes Metab Syndr. 2020;14(4):513-517. doi:10.1016/j.dsx.2020.04.049
10. Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in COVID-19. N Engl J Med. 2020;383(8):789-790. doi:10.1056/NEJMc2018688
11. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-310. doi:10.1016/j.dsx.2020.04.004
12. Klonoff DC, Umpierrez GE. COVID-19 in patients with diabetes: risk factors that increase morbidity. Metabolism. 2020;108:154224. doi:10.1016/j.metabol.2020.154224
13. Maddaloni E, Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020;36(7):e3321. doi:10.1002/dmrr.3321
14. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43(6):867-869. doi:10.1007/s40618-020-01236-2
15. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? Diabetes Metab Syndr. 2020;14(4):535-545. doi:10.1016/j.dsx.2020.04.044
16. Gianchandani R, Esfandiari NH, Ang L, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69(10):2048-2053. doi:10.2337/dbi20-0022
17. Umpierrez GE, Klonoff DC. Diabetes technology in the inpatient setting during the COVID-19 pandemic. J Diabetes Sci Technol. 2020;14(4):795-797. doi:10.1177/1932296820935175
18. Rayman G, Lumb A, Kennon B, et al. Guidance on inpatient diabetes care during the COVID-19 pandemic. Diabet Med. 2020;37(7):1087-1089. doi:10.1111/dme.14370
19. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes. Diabetologia. 2020;63(8):1500-1515. doi:10.1007/s00125-020-05180-x
20. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes. Lancet Diabetes Endocrinol. 2020;8(10):823-833. doi:10.1016/S2213-8587(20)30271-0
21. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for severe COVID-19. Diabetes Metab. 2020;46(6):438-445. doi:10.1016/j.diabet.2020.07.006
22. Misra A, Ghosh A, Gupta R. Heterogeneity in presentation of COVID-19 in type 2 diabetes. Diabetes Metab Syndr. 2020;14(4):453-457. doi:10.1016/j.dsx.2020.04.017
23. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi:10.1016/S2213-8587(20)30272-2
24. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection. Diabetes Care. 2021;44(1):55-65. doi:10.2337/dc20-2155
25. Khunti K, Del Prato S, Mathieu C, et al. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021;44(12):2645-2655. doi:10.2337/dc21-1318
26. Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review. Diabetes Obes Metab. 2021;23(3):870-874. doi:10.1111/dom.14269
27. Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis. Diabetes Metab Syndr. 2020;14(6):1563-1569. doi:10.1016/j.dsx.2020.08.015
28. Ghosh A, Gupta R, Misra A. Telemedicine for diabetes care in India during COVID-19. Diabetes Metab Syndr. 2020;14(5):933-936. doi:10.1016/j.dsx.2020.06.039
29. Wargny M, Potier L, Gourdy P, et al. Predictors of hospital discharge and mortality in COVID-19 patients with diabetes. Diabetologia. 2021;64(1):1-12. doi:10.1007/s00125-020-05328-8
30. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341-342. doi:10.1038/s41574-020-0364-6
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright Policy & Licensing terms | Tropical Journal of Pharmaceutical and Life Sciences
